Loading…
Employees: 211
Size Shukra Pharmaceuticals (SHUKRAPHAR.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $372M, the 969th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹79.88 on 6 Nov 2026.
Growth Revenue grew 115.1% over the last twelve months (peer median +2.3%); the operating margin is 57.2% (peer median -13.4%).
Valuation It trades at 46.9× enterprise value to sales against a peer median of 3.2× (3rd most expensive of 16).
Capital Return on invested capital runs 26.3 points above its cost of capital (9.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹749M | ₹567M | ₹326M | ₹746M | ₹588M |
| Revenue growth | — | +74% | -56% | +27% | — |
| Gross profit | ₹480M | ₹306M | ₹156M | ₹230M | ₹66.1M |
| EBITDA | ₹466M | ₹290M | ₹127M | ₹195M | ₹64.6M |
| Net income | ₹340M | ₹220M | ₹95.8M | ₹185M | ₹44.1M |
| Free cash flow | n/a | -₹120M | ₹60.6M | -₹66.8M | -₹15.1M |
| Capital expenditure | n/a | ₹157M | ₹27.4M | ₹17.6M | ₹44.9M |
| Total debt | n/a | ₹50.2M | ₹41.8M | ₹31.5M | ₹50.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SHUKRAPHAR.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.9% | -12.0% | highest of 20 |
| Distance from 52-week high | -5.1% | -38.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +115.1% | +2.3% | 3rd highest of 18 |
| Operating margin | 57.2% | -13.4% | highest of 17 |
| EV / Sales | 46.9× | 3.2× | 3rd most expensive of 16 |
| ROIC minus cost of capital | +26.3 pp | -8.9 pp | highest of 16 |
| EV / EBITDA | 75.4× | 12.4× | most expensive of 5 |
| Net debt / EBITDA | -0.0× | 0.9× | 3rd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shukra Pharmaceuticals SHUKRAPHAR.NS | India | $372M | n/a | +115% | 57% | 46.9× | n/a | n/a |
| Avalo Therapeutics AVTX | United States | $372M | -68% | -87% | -154,844% | n/a | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $372M | -17% | -24% | 3% | 1.1× | 4.2% | +3.1% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $372M | -23% | +2% | -6% | 8.3× | 16.3% | -14.0% |
| Unichem Laboratories UNICHEMLAB.NS | India | $373M | +28% | +9% | 5% | 1.5× | n/a | n/a |
| Rezolute RZLT | United States | $375M | +21% | n/a | n/a | n/a | n/a | n/a |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $368M | -25% | +3% | 6% | 1.8× | 13.2% | +6.5% |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $376M | -21% | -26% | -15% | 2.0× | 9.0% | -11.3% |
| Hinova Pharmaceuticals 688302.SS | China | $366M | -24% | +251% | -195% | 22.0× | n/a | n/a |
| TRex Bio TRXB | United States | $364M | n/a | -100% | n/a | n/a | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| JCR Pharmaceuticals 4552.T | Japan | $383M | -11% | +3% | -14% | 2.9× | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $385M | -75% | n/a | n/a | n/a | n/a | n/a |
| iX Biopharma 42C.SI | Singapore | $386M | +10% | -12% | -140% | 70.7× | n/a | n/a |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $392M | +15% | -1% | -13% | 5.2× | 23.2% | -15.7% |
| Heartseed 219A.T | Japan | $393M | +52% | +197% | 9% | 21.4× | 50.0% | +73.2% |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |
| SanBio 4592.T | Japan | $393M | -58% | n/a | n/a | n/a | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $395M | -6% | +69% | -16% | 5.8× | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | 3.1× | n/a | n/a |